Acasti Pharma Inc. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Note 12 - Derivative Warrant Liabilities (Tables)

Note 12 - Derivative Warrant Liabilities (Tables)

12 Months Ended

Mar. 31, 2019

Statement Line Items [Line Items]

Disclosure of maturity analysis for derivative financial liabilities [text block]

		Warrant liabilities issued May 2018								Warrant liabilities issued December 27, 2017								Warrant liabilities issued December 3, 2013 1
		March 31, 2019				March 31, 2018				March 31, 2019				March 31, 2018				March 31, 2019				March 31, 2018
		$				$				$				$				$				$
Balance – beginning of period			-				-				6,405				-				21				209
Issued during period			4,272				-				-				5,873				-				-
Exercised during period			(722	)			-				-				-				-				-
Change in fair value of derivative warrant liabilities			4,696				-				1,612				532				(21	)			(188	)
Balance – end of period			8,246				-				8,017				6,405				-				21

Fair value per share issuable			0.81				-				0.82				0.65				-				0.01

Derivative warrant liabilities [member]

Statement Line Items [Line Items]

Disclosure of sensitivity analysis for actuarial assumptions [text block]

		Warrant liabilities issued May 2018								Warrant liabilities issued December 27, 2017								Warrant liabilities issued December 3, 2013 1
		March 31, 2019				March 31, 2018				March 31, 2019				March 31, 2018				March 31, 2019				March 31, 2018
Exercise price		$	1.31				-				US $1.26				US $1.26				-				US $1.50
Share price		$	1.35				-				US $1.02				US $1.02				-				US $1.02
Risk-free interest			1.52	%			-				2.23	%			2.56	%			-				2.19	%
Estimated life (in years)			4.11				-				3.75				4.75				-				0.68
Expected volatility			94.58	%			-				107.57	%			95.15	%			-				133.86	%